Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan 10;19(1):5.
doi: 10.1186/s12893-018-0465-5.

Surgical therapy of primary hepatic angiosarcoma

Verena Tripke  1 , Stefan Heinrich  1 , Tobias Huber  1 , Jens Mittler  1 , Maria Hoppe-Lotichius  1 , Beate K Straub  2 , Hauke Lang  3
Affiliations

Surgical therapy of primary hepatic angiosarcoma

Verena Tripke et al. BMC Surg. .

Abstract

Background: Primary hepatic angiosarcoma (PHA) is a rare tumor entity. Radical surgical resection is currently considered the best treatment choice. The aim of this analysis is to report our experience with surgery for PHA.

Methods: All resections of PHA from 01/2002 until 06/2017 were identified from our prospective institutional database. All cases were re-confirmed by a second pathologist. We analyzed completeness of resection, overall (OS) and disease-free survival (DFS).

Results: Nine patients with PHA underwent hepatic resection. Median follow-up after surgery was 15.5 months (range: 3-144). At last follow-up 4/9 patients were alive, three of them without recurrence 15, 21 and 144 months after surgery. Five patients developed PHA recurrence. Four of these died 3 to 17 months after surgery. One patient with PHA recurrence is alive 15 months after surgery. Another patient without PHA recurrence died 59 months after surgery from pancreatic cancer. Median OS and DFS after resection was 18 months (range: 3-144 months) and 10 months (range: 2-144 months), respectively. After R-0 resection (n = 8), the median OS and DFS was 59 and 11 months.

Conclusions: Resection of PHA is the only approach to achieve complete tumor removal and offers a chance for long-term survival and should be evaluated in cases of PHA.

Keywords: Liver malignancies; Liver resection; Surgical oncology.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Overall survival of patients with PHA after surgery (n = 9) and after R0-resection (n = 8)
Fig. 2
Fig. 2
Preoperative contrast enhanced computed tomography scan showed a heterogenous mass in the right liver lobe (a and b)
Fig. 3
Fig. 3
Pathology findings (hematoxylin and eosin staining, × 200) showing sinusoidal and spindle-shape growth of the malignant endothelial cells: G1 (a), G2 (b) and G3 (c)
See this image and copyright information in PMC

References

    1. Molina E, Hernandez A. Clinical manifestations of primary hepatic angiosarcoma. Dig Dis Sci. 2003;48:677–682. doi: 10.1023/A:1022868221670. - DOI - PubMed
    1. Elliott P, Kleinschmidt I. Angiosarcoma of the liver in Great Britain in proximity to vinyl chloride sites. Occup Environ Med. 1997;54:14–18. doi: 10.1136/oem.54.1.14. - DOI - PMC - PubMed
    1. Salgado M, Sans M, Forns X, Bruguera M, Castells A, Navasa M, Rodés J. Hepatic angiosarcoma: a report of a case associated with treatment with arsenic salts and a review of the literature. Gastroenterol Hepatol. 1995;18:132–135. - PubMed
    1. Kojiro M, Nakashima T, Ito Y, Ikezaki H. Pathomorphological study on thorotrast-induced hepatic malignancies. Strahlentherapie Sonderb. 1985;80:119–122. - PubMed
    1. Falk H, Thomas LB, Popper H, Ishak KG. Hepatic angiosarcoma associated with androgenic-anabolic steroids. Lancet. 1979;2:1120–1123. doi: 10.1016/S0140-6736(79)92515-7. - DOI - PubMed